Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
exarafenib (KIN-2787) / Pierre Fabre
KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors	Recruiting	1	400	Europe, US, RoW	KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib	Pierre Fabre Medicament	Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma	12/24	12/25